Safety and tolerability of increasing doses of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase, in solid tumors.-Reference-Cited by-同舟云学术

Safety and tolerability of increasing doses of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase, in solid tumors.

Published:2015-05-20 Issue:15_suppl Volume:33 Page:2512-2512
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Harding James J.¹,Telli Melinda L.²,Munster Pamela N.³,Le Mai H.⁴,Molineaux Christopher⁴,Bennett Mark K.⁵,Mittra Erik²,Burris Howard A.⁶,Clark Amy Sanders⁷,Dunphy Mark⁸,Meric-Bernstam Funda⁹,Patel Manish R.¹⁰,DeMichele Angela¹¹,Infante Jeffrey R.¹²

Affiliation:

1. Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

2. Stanford University School of Medicine, Stanford, CA

3. University of California, San Francisco, San Francisco, CA

4. Calithera Biosciences, Inc., South San Francisco, CA

5. Calithera Biosciences Inc, South San Francisco, CA

6. Sarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, TN

7. Hosp of the Univ of Penn, Philadelphia, PA

8. Memorial Sloan Kettering Cancer Center, New York, NY

9. The University of Texas MD Anderson Cancer Center, Houston, TX

10. Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL

11. Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA